Small Molecule Protein-Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future Hurdles

被引:145
作者
Blazer, Levi L. [1 ]
Neubig, Richard R. [1 ,2 ,3 ]
机构
[1] Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Ctr Chem Genom, Ann Arbor, MI 48109 USA
关键词
protein-protein interaction; RGS; small molecule; PDZ; amyloid-beta; a-synuclein; AMYLOID-BETA AGGREGATION; ENDOGENOUS RGS PROTEINS; SYSTEM DRUG TARGETS; G184S GNAI2 ALLELE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; NEURODEGENERATIVE DISEASES; SUSCEPTIBILITY GENE; PDZ-DOMAIN;
D O I
10.1038/npp.2008.151
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Protein-protein interactions are a crucial element in cellular function. The wealth of information currently available on intracellular-signaling pathways has led many to appreciate the untapped pool of potential drug targets that reside downstream of the commonly targeted receptors. Over the last two decades, there has been significant interest in developing therapeutics and chemical probes that inhibit specific protein-protein interactions. Although it has been a challenge to develop small molecules that are capable of occluding the large, often relatively featureless protein-protein interaction interface, there are increasing numbers of examples of small molecules that function in this manner with reasonable potency. This article will highlight the current progress in the development of small molecule protein-protein interaction inhibitors that have applications in the treatment or study of central nervous system function and disease. In particular, we will focus upon recent work towards developing small molecule inhibitors of amyloid-beta and alpha-synuclein aggregation, inhibitors of critical components of G-protein-signaling pathways, and PDZ domain inhibitors.
引用
收藏
页码:126 / 141
页数:16
相关论文
共 160 条
[151]   Between a rock and a hard place? [J].
Whitty, A ;
Kumaravel, G .
NATURE CHEMICAL BIOLOGY, 2006, 2 (03) :112-118
[152]  
Wieland T, 1997, J BIOL CHEM, V272, P8853
[153]   Support for RGS4 as a susceptibility gene for schizophrenia [J].
Williams, NM ;
Preece, A ;
Spurlock, G ;
Norton, N ;
Williams, HJ ;
McCreadie, RG ;
Buckland, P ;
Sharkey, V ;
Chowdari, KV ;
Zammit, S ;
Nimgaonkar, V ;
Kirov, G ;
Owen, MJ ;
O'Donovan, MC .
BIOLOGICAL PSYCHIATRY, 2004, 55 (02) :192-195
[154]   Significant support for DAO as a schizophrenia susceptibility locus: Examination of five genes putatively associated with schizophrenia [J].
Wood, Linda S. ;
Pickering, Eve H. ;
Dechairo, Bryan M. .
BIOLOGICAL PSYCHIATRY, 2007, 61 (10) :1195-1199
[155]   Structural basis for the selectivity of the RGS protein, GAIP, for Gαi family members -: Identification of a single amino acid determinant for selective interaction of Gαi subunits with GAIP [J].
Woulfe, DS ;
Stadel, JM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) :17718-17724
[156]   Tramiprosate [J].
Wright, Tamsin M. .
DRUGS OF TODAY, 2006, 42 (05) :291-298
[157]   Genetic alteration of phospholipase C β3 expression modulates behavioral and cellular responses to μ opioids [J].
Xie, W ;
Samoriski, GM ;
McLaughlin, JP ;
Romoser, VA ;
Smrcka, A ;
Hinkle, PM ;
Bidlack, JM ;
Gross, RA ;
Jiang, HP ;
Wu, DQ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (18) :10385-10390
[158]   A spatial focusing model for G protein signals - Regulator of G protein signaling (RGS) protein-mediated kinetic scaffolding [J].
Zhong, HL ;
Wade, SM ;
Woolf, PJ ;
Linderman, JJ ;
Traynor, JR ;
Neubig, RR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (09) :7278-7284
[159]  
Zhong HL, 2001, J PHARMACOL EXP THER, V297, P837
[160]   The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils [J].
Zhu, M ;
Rajamani, S ;
Kaylor, J ;
Han, S ;
Zhou, FM ;
Fink, AL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (26) :26846-26857